Michael Freissmuth

Title: Innovations by Michael Freissmuth

Introduction

Michael Freissmuth is a notable inventor based in Vienna, Austria. He has made significant contributions to the field of haematopoetic stem cell transplantation. With a total of five patents to his name, Freissmuth's work focuses on enhancing the efficacy of stem cell engraftment.

Latest Patents

Freissmuth's latest patents include a composition for increasing engraftment efficacy of haematopoetic stem cells after transplantation. This invention provides a new use of a composition comprising at least one inhibitor of dipeptidyl peptidase IV (DPP-IV) to enhance the migration and homing of haematopoetic progenitor cells in recipients. Another significant patent is a method for enhancing engraftment of haematopoetic stem cells through an ex-vivo pretreatment process. This method involves obtaining a sample of haematopoetic stem cells and admixing a prostacyclin analog to stimulate G alphas-signalling in the cells.

Career Highlights

Throughout his career, Freissmuth has worked with various companies, including Scipharm Sarl and Igeneon Krebs-Immuntherapie Forschungs-und Entwicklungs-AG. His innovative approaches have contributed to advancements in stem cell therapies.

Collaborations

Freissmuth has collaborated with notable colleagues such as Eva-Maria Zebedin-Brandl and Xaver Koenig. Their joint efforts have furthered research in the field of haematopoetic stem cell transplantation.

Conclusion

Michael Freissmuth's contributions to stem cell research and his innovative patents have made a significant impact in the medical field. His work continues to pave the way for advancements in transplantation therapies.